Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(TSX: BLCO )

19.92 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 19.92
Bid (Size) 19.28 (2)
Ask (Size) 20.90 (4)
Prev. Close 19.92
Today's Range 19.92 - 19.92
52wk Range 18.41 - 28.10
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes
From Bausch + Lomb Corporation
Via Business Wire

Performance

YTD
-11.43%
-11.43%
1 Month
-14.29%
-14.29%
3 Month
+3.43%
+3.43%
6 Month
-10.51%
-10.51%
1 Year
-15.70%
-15.70%

More News

Read More
Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
From Bausch + Lomb
Via Business Wire
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.